CRISPR Therapeutics (NASDAQ: CRSP) it is a leading biotech company, but it is not yet profitable. That’s why its shares have fallen slightly so far this year.
There are many reasons, however, to be bullish on the stock, not the least of which is its improved cash position. The company had nearly $2 billion in cash, cash equivalents, and marketable securities at the end of 2025.
Will AI create the world’s first trillionaire? Our team recently released a report on one little-known company, called “Indispensable Monopoly” that provides essential technology needed by both Nvidia and Intel. Continue »
That kind of cushion gives the company breathing room to boost sales of its only approved gene-editing therapy, Casgevy, which is used as a one-time treatment for sickle cell disease and transfusion-dependent beta thalassemia. Casgevy, priced at $2.2 million per treatment, had $116 million in 2025 sales, including $54 million in the fourth quarter alone, indicating that its sales are accelerating. Still, the company lost $578.6 million last year.
CRISPR gene editing has the potential to treat disease patients, not just cure themselves. Casgevy has already shown that it can be an effective remedy. The problem, at the moment, is that Casgevy is very expensive and only treats a small part of the population.
However, CRISPR already has five other treatments in clinical trials on its way, including those with the largest markets. The biotech company’s strong financial position gives it time to bring some of these treatments through the approval process.
Three with broad promise are CXT310 and CXT320 for cardiovascular disease and CTX112 for various cancers and autoimmune disorders. CTX310 and CTX320 are “in vivo” gene editing therapies, meaning they are designed to edit genes directly in the body. Both of these treatments aim to reduce the risk of heart disease by lowering blood lipids in the liver.
CTX112, commonly known as zugo-cel (abbreviated as zugocaptagene geleucel), CRISPR Therapeutics’ next-generation “off-the-shelf” (allogeneic) CAR T-cell therapy. It is being tested in autoimmune disorders such as lupus and systemic sclerosis, two rare diseases, but it is also being seen as a potential treatment for B-cell cancer, the most common form of blood cancer in the US.
Before buying stock in CRISPR Therapeutics, consider the following:
I The Motley Fool Stock Advisor a team of analysts has just identified what they believe to be 10 best stocks for investors to buy now… and CRISPR Therapeutics was not one of them. The 10 stocks that made the cut could produce huge gains in the coming years.
Think about when Netflix made this list on December 17, 2004… if you invested $1,000 during our recommendation, you will have $555,526!* Whenever Nvidia made this list on April 15, 2005… if you invested $1,000 during our recommendation, you will have $1,156,403!*
Now, it’s worth noting Stock Advisor’s the average total return is 968% – outperformed the market by 191% for the S&P 500. Don’t miss the latest top 10 list, available via Stock Advisorand join an investment community built by individual investors for individual investors.
See 10 stocks »
*The Stock Advisor returns as of April 13, 2026.
James Halley holds positions in CRISPR Therapeutics. The Motley Fool has a position on and recommends CRISPR Therapeutics. The Motley Fool has a policy of disclosure.
2 Billion Reasons to Love CRISPR Therapeutics Right Now was originally published by The Motley Fool
